WallStreetZenWallStreetZen

NASDAQ: THAR
Tharimmune Inc Stock Ownership - Who owns Tharimmune?

Insider buying vs selling

Have Tharimmune Inc insiders been buying or selling?
Buy
Sell
NameRoleDateSharesPriceValue
Randy MilbyCEO2023-12-1529,000$0.50
$14.59kBuy
Randy MilbyCEO2023-11-3010,000$1.00
$10.00kBuy

1 of 1

THAR insiders have bought more... subscribe to Premium to read more.
Net Insider Buy/Sell (L12M) Ownership

Be the first to know when THAR insiders and whales buy or sell their stock.

THAR Shareholders

What type of owners hold Tharimmune Inc stock?
Institutional
Insider
Retail
NameHoldSharesValueType
Highpoint Pharmaceuticals LLC8.28%972,222$368.47kInsider
Kufe LLC6.90%810,395$307.14kInsider
Surender Kharbanda6.14%721,240$273.35kInsider
Varinder Kaur5.56%653,059$247.51kInsider
Sandeep Laumas5.42%636,008$241.05kInsider
Sireesh Appajosyula2.48%291,666$110.54kInsider
Randy Milby1.33%156,517$59.32kInsider
Leonard L. Mazur1.05%123,733$46.89kInsider
Virtu Financial LLC0.89%105,033$39.81kInstitution
Citadel Advisors LLC0.17%19,727$7.48kInstitution

1 of 2

THAR vs Biotech Stocks

TickerInst. %Insider %Net Insider (L12M)Net Insider (L3M)
THAR1.16%37.18%Net Buying
CING0.05%99.95%Net BuyingNet Buying
ARTL0.76%25.83%
LGVN14.25%85.75%Net BuyingNet Buying
TCON6.34%93.66%Net Selling

Tharimmune Stock Ownership FAQ

Who owns Tharimmune?

Tharimmune (NASDAQ: THAR) is owned by 1.16% institutional shareholders, 37.18% Tharimmune insiders, and 61.66% retail investors. Highpoint Pharmaceuticals LLC is the largest individual Tharimmune shareholder, owning 972,222.00 shares representing 8.28% of the company. Highpoint Pharmaceuticals LLC's Tharimmune shares are currently valued at $361.67k.

If you're new to stock investing, here's how to buy Tharimmune stock.
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.